Spinal fluid chemo cocktail targets tough brain cancer spread
NCT ID NCT06663306
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early study tests whether injecting two cancer drugs (pemetrexed and bevacizumab) directly into the spinal fluid is safe for people with a specific type of lung cancer that has spread to the lining of the brain. The trial will enroll 19 adults whose cancer has worsened despite standard treatment. The main goal is to check for side effects, but researchers will also track how long participants live.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
pemetrexed and bevacizumab
What this could lead to
If it works, this could point toward a new treatment option for lung cancer that has spread to the lining of the brain, a condition with very few options.
What could go wrong
This is a very early phase 1 trial with only 19 people, so it is primarily testing safety, not effectiveness. The drugs are given directly into the spinal fluid, which carries risks like infection or nerve damage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEPTOMENINGEAL METASTASIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai Chest Hospital
RECRUITINGShanghai, 200030, China
Contact Phone: •••-•••-•••• Email: •••••@•••••